Autologous, Allogeneic Hematopoietic Cell Transplantation and CAR-T/NK Therapy: What is Their Real Importance in PTCL?

Overview

Journal Front Oncol

Specialty Oncology

Date 2023 Sep 15

PMID 37711206

Authors

Samuel C F Couto

Ariel Kowes

Camila S Aurabi

Theo G M Oliveira

Paulo Klinger

Vanderson Rocha

Affiliations

Soon will be listed here.

Abstract

Peripheral T cell lymphoma (PTCL) is a rare and aggressive type of non-Hodgkin's lymphoma that affects mature T cells. This type of cancer is characterized by the abnormal growth of T cells, which can accumulate in the lymph nodes, spleen, bone marrow, and other organs, leading to a variety of symptoms. PTCLs are often difficult to diagnose and treat, and they have a poorer prognosis than other types of lymphoma. However, recent advancements in treatment options, such as targeted therapies have shown promise in improving outcomes for patients with PTCL. Here, we discuss the use of autologous and allogeneic hematopoietic cell transplantation (HCT) as a treatment strategy for patients with PTCL, as well as the recent treatment approaches based on advanced cellular therapy. The current evidence for the use of HCT in PTCL is mainly derived from registry data, retrospective studies, and expert opinion, as randomized trials are limited due to the low incidence and histological heterogeneity of PTCL subtypes.

Citing Articles

Broadening the horizon: potential applications of CAR-T cells beyond current indications.

Karsten H, Matrisch L, Cichutek S, Fiedler W, Alsdorf W, Block A Front Immunol. 2023; 14:1285406.

PMID: 38090582 PMC: 10711079. DOI: 10.3389/fimmu.2023.1285406.

References

Bellei M, Foss F, Shustov A, Horwitz S, Marcheselli L, Kim W . The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project. Haematologica. 2018; 103(7):1191-1197. PMC: 6029527. DOI: 10.3324/haematol.2017.186577. View

Zhang J, Briski R, Devata S, Kaminski M, Phillips T, Mayer T . Survival following salvage therapy for primary refractory peripheral T-cell lymphomas (PTCL). Am J Hematol. 2017; 93(3):394-400. PMC: 5803354. DOI: 10.1002/ajh.24992. View

Hu Y, Zhou Y, Zhang M, Zhao H, Wei G, Ge W . Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study. Cell Res. 2022; 32(11):995-1007. PMC: 9652391. DOI: 10.1038/s41422-022-00721-y. View

Lu P, Liu Y, Yang J, Zhang X, Yang X, Wang H . Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL: first-in-human phase 1 clinical trial. Blood. 2022; 140(4):321-334. DOI: 10.1182/blood.2021014498. View

Pinz K, Yakaboski E, Jares A, Liu H, Firor A, Chen K . Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells. Oncotarget. 2018; 8(68):112783-112796. PMC: 5762550. DOI: 10.18632/oncotarget.22626. View

Rohlfing S, Dietrich S, Witzens-Harig M, Hegenbart U, Schonland S, Luft T . The impact of stem cell transplantation on the natural course of peripheral T-cell lymphoma: a real-world experience. Ann Hematol. 2018; 97(7):1241-1250. DOI: 10.1007/s00277-018-3288-7. View

Alaggio R, Amador C, Anagnostopoulos I, Attygalle A, de Oliveira Araujo I, Berti E . The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022; 36(7):1720-1748. PMC: 9214472. DOI: 10.1038/s41375-022-01620-2. View

Heczey A, Courtney A, Montalbano A, Robinson S, Liu K, Li M . Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis. Nat Med. 2020; 26(11):1686-1690. DOI: 10.1038/s41591-020-1074-2. View

Chen A, McMillan A, Negrin R, Horning S, Laport G . Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience. Biol Blood Marrow Transplant. 2008; 14(7):741-7. PMC: 2980839. DOI: 10.1016/j.bbmt.2008.04.004. View

10.

Phillips E, Lannon M, Lopes A, Chadwick H, Jones G, Sieniawski M . High-dose chemotherapy and autologous stem cell transplantation in enteropathy-associated and other aggressive T-cell lymphomas: a UK NCRI/Cancer Research UK Phase II Study. Bone Marrow Transplant. 2018; 54(3):465-468. DOI: 10.1038/s41409-018-0294-2. View

11.

Kruschinski A, Moosmann A, Poschke I, Norell H, Chmielewski M, Seliger B . Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas. Proc Natl Acad Sci U S A. 2008; 105(45):17481-6. PMC: 2582261. DOI: 10.1073/pnas.0804788105. View

12.

Pan J, Tan Y, Wang G, Deng B, Ling Z, Song W . Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial. J Clin Oncol. 2021; 39(30):3340-3351. DOI: 10.1200/JCO.21.00389. View

13.

Maciocia P, Wawrzyniecka P, Philip B, Ricciardelli I, Akarca A, Onuoha S . Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies. Nat Med. 2017; 23(12):1416-1423. DOI: 10.1038/nm.4444. View

14.

Delioukina M, Zain J, Palmer J, Tsai N, Thomas S, Forman S . Reduced-intensity allogeneic hematopoietic cell transplantation using fludarabine-melphalan conditioning for treatment of mature T-cell lymphomas. Bone Marrow Transplant. 2011; 47(1):65-72. PMC: 3130104. DOI: 10.1038/bmt.2011.16. View

15.

Jacobsen E, Kim H, Ho V, Cutler C, Koreth J, Fisher D . A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome. Ann Oncol. 2011; 22(7):1608-1613. PMC: 3121969. DOI: 10.1093/annonc/mdq698. View

16.

Tonn T, Schwabe D, Klingemann H, Becker S, Esser R, Koehl U . Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherapy. 2013; 15(12):1563-70. DOI: 10.1016/j.jcyt.2013.06.017. View

17.

Savage K, Horwitz S, Advani R, Haaber Christensen J, Domingo-Domenech E, Rossi G . Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2. Blood Adv. 2022; 6(19):5550-5555. PMC: 9647727. DOI: 10.1182/bloodadvances.2020003971. View

18.

Matsushita H, Vesely M, Koboldt D, Rickert C, Uppaluri R, Magrini V . Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature. 2012; 482(7385):400-4. PMC: 3874809. DOI: 10.1038/nature10755. View

19.

Park S, Horwitz S, Foss F, Pinter-Brown L, Carson K, Rosen S . The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study. Cancer. 2019; 125(9):1507-1517. PMC: 8269282. DOI: 10.1002/cncr.31861. View

20.

OConnor O, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B . Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011; 29(9):1182-9. PMC: 3083873. DOI: 10.1200/JCO.2010.29.9024. View